Milestone Pharmaceuticals Inc. MIST
0.58 USD -0.08 (-12.21%)
Nov 13, 2026, 10:34 AM EST
0.5517 Day range 0.70
0.5517 52-week range 3.06
- YTD
- -71.52%
- 1 year
- -69.73%
Benzinga news
benzinga.com Milestone Pharmaceuticals Announces Cost-Efficiency Measures To Reduce Its Opex By ~30%, Completed By Q1 2027; Expects To Incur ~$2M In One-Time Charges Key elements of the cost-efficiency measures include:Bringing the sales force in-house: the Company plans to retain the existing field sales team of approximately 45 dedicated representatives,…
benzinga.com Milestone Pharmaceuticals Q3 EPS $(0.18) Beats $(0.21) Estimate, Sales $2.963M Beat $1.143M Estimate Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 50 percent decrease over losses…
benzinga.com HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.- benzinga.com Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone
benzinga.com Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026 Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a…
benzinga.com This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page for full details and stock recommendations.- benzinga.com Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3 Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and announces Price Target of $3.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics- benzinga.com Milestone Pharmaceuticals Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $559.000K Miss $816.667K Estimate Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 10.53 percent. This is a 5 percent decrease over…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
benzinga.com Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7 Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $8 to $7.
benzinga.com Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported first-quarter earnings on Wednesday before the market opened.
benzinga.com Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Milestone Expands CARDAMYST Push Into Europe, China And New AFib Trial Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Why Milestone Pharma Stock Is Taking A Dive Today EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, solid sales beat and cash runway into 2027.
benzinga.com Milestone Pharmaceuticals Q4 EPS $(0.16), Inline, Sales $1.546M Beat $1.200M Estimate Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 15.79 percent increase over losses of $(0.19) per share from…- benzinga.com Earnings Scheduled For March 20, 2026
benzinga.com Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.- benzinga.com Milestone Pharmaceuticals Announces Availability Of Cardamyst (Etripamil) Nasal Spray, Its First Commercial Product, Through US Retail Pharmacies CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Implementation of a…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com AptarGroup Announces That Its Bidose Liquid Nasal Spray System Liquid Is The Mechanism For Delivering The Newly Approved CARDAMYST Aptar Group, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the…
benzinga.com Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8 Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and raises the price target from $4 to $8.
benzinga.com TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and announces $8 price target.- benzinga.com HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Raises Price Target to $8 HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and raises the price target from $5 to $8.
benzinga.com Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for PSVT in 30 years.- benzinga.com Market-Moving News for December 15th RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved…
- benzinga.com Reported Friday, Milestone Wins FDA Approval For CARDAMYST, First Self-Administered Nasal Spray For Paroxysmal Supraventricular Tachycardia First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Milestone Pharmaceuticals Q3 EPS $(0.12) Beats $(0.16) Estimate Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 26.83 percent. This is a 14.29 percent increase over…
- benzinga.com Milestone Pharma Says New Data Analyses Of Investigational Product For PSVT, Etripamil Nasal Spray, Consistently Showed Efficacy And Favorable Safety Profile Across Multiple Studies Comprising Global Development Program Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that new data…
benzinga.com Wells Fargo Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $4 Wells Fargo analyst Mohit Bansal initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and announces Price Target of $4.- benzinga.com Milestone Pharmaceuticals Q2 EPS $(0.20) Misses $(0.17) Estimate Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 42.86 percent decrease over…
benzinga.com Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Why Is Milestone Pharmaceuticals Stock Plunging On Friday? FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch.
benzinga.com Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings - benzinga.com Milestone Pharma Prices $52.5M Equity Offering With Warrants; Offering Is Expected To Close On Or About July 14, 2025 Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Assumes Milestone Pharmaceuticals at Buy, Announces Price Target of $5 HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announces Price Target of $5.
- benzinga.com Milestone Pharmaceuticals Q1 EPS $(0.31) Misses $(0.18) Estimate Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.18) by 72.22 percent. This is a 47.62 percent decrease over…
- benzinga.com HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $10 HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $25 to $10.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $25 price target.
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Why Is Milestone Pharmaceuticals Stock Plunging Today? Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Milestone Pharmaceuticals Says FDA Issued Complete Response Letter Regarding Its New Drug Application For CARDAMYST Nasal Spray The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highlighted two key Chemistry, Manufacturing and Controls (CMC) issues to be addressed.